Knowledge Ecology International

Save the Date: Thursday, 17 October 2024 – Innovarte/KEI side event: Best and worst practices for limitations and exceptions to patent rights

Posted on October 10, 2024 by Thiru

Title: Best and worst practices for limitations and exceptions to patent rights Date: Thursday, 17 October 2024 Time: 13:30 CEST to 15:00 CEST Location: Room B, WIPO Registration link: https://wipo-int.zoom.us/meeting/register/u5Mtf-6vqz0jGdWIE2AObIjgN86Xuy4yqaKi Conveners: Innovarte and Knowledge Ecology International (KEI) On the margins… Continue Reading →

KEI Asks FDA to Publish Historical Orange Book Data

Posted on October 3, 2024 by Claire Cassedy

On October 3, 2023, Knowledge Ecology International (KEI) sent a letter to the FDA asking the agency to publish its historical Orange Book data. The Orange Book identifies patent and exclusivity data for FDA approved drug products. The FDA publicly… Continue Reading →

KEI asks HHS to stop opposing the publishing of terms regarding equitable access in funding contracts

Posted on September 19, 2024 by James Love

KEI2HHS19Sep2024 September 19, 2024 Emily Bleimund, JD, MA Director, Office of Trade and Health U.S. Department of Health and Human Services Steven T. Smith National Institute of Allergy and Infectious Diseases (NIAID) Representative, Geneva, Switzerland Dear Emily and Steven, I… Continue Reading →

September 16, 2024 version of the negotiating text for a WHO pandemic agreement

Posted on September 17, 2024 by James Love

The WHO has shared the end of day September 16, 2024 version of the negotiating text for a WHO pandemic agreement. who-pandemic-agreement-16Sep-17.30

INB11: KEI statement on Article 13 (on sanctions)

Posted on September 12, 2024 by Thiru

On Thursday, 12 September 2024, non-State actors in official relations and relevant stakeholders were invited to join a “brief open session at the beginning of the day.” In advance of Thursday’s discussions on Article 13 (Supply chain and logistics) and… Continue Reading →

KEI comment to USPTO on the need for a statutory experimental use exception for patents

Posted on September 10, 2024 by James Love

The USPTO has a request for comment on the need for a statutory experimental use exception for patents. (89 FR 53963). The USPTO uploads the comments to Regulations.Gov, docket PTO-C-2024-0023. KEI filed comments on September 10, 2024: KEI-Experimental-use-exception-10Sept2024 September 10,… Continue Reading →

INB11: Statement of Knowledge Ecology International (KEI) – Complementarity and coherence

Posted on September 9, 2024 by Thiru

On Monday afternoon, 9 September 2024, Knowledge Ecology International (KEI) delivered this statement on the complementarity and coherence between the amended International Health Regulations (2005), adopted by the Seventy‑seventh World Health Assembly, and the proposal for the WHO Pandemic Agreement… Continue Reading →

INB11: Statement of Knowledge Ecology International (KEI) – Legal architecture of the proposal for the WHO Pandemic Agreement

Posted on September 9, 2024 by Thiru

On Monday afternoon, 9 September 2024, Knowledge Ecology International (KEI) delivered this statement on the legal architecture of the proposal for the WHO Pandemic Agreement. KEI has an open mind regarding the appropriate nature of the instrument or instruments for… Continue Reading →

KEI Comments on NIH Exclusive License to Autala for Autoimmune Treatment

Posted on September 4, 2024 by Claire Cassedy

On September 3, 2024, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases” (89 FR 66730). The Federal Register notice… Continue Reading →

KEI letter to the NIH regarding need for better reporting on the utilization of licensed inventions and access in developing countries

Posted on August 28, 2024 by James Love

The PDF version of the letter has all tables and footnotes: KEI-NIH-28Aug2028 August 28, 2024 Abby Rives, JD Division Director Technology Transfer and Innovation Policy National Institutes for Health Vladimir Knezevic, MD Senior Advisor for Commercial Evaluation Technology Advancement Office… Continue Reading →

Categories